BE628497A - Nouveau composé utilisable notamment pour le traitement des manifestations inflammatoires et/ou douloureuses - Google Patents

Nouveau composé utilisable notamment pour le traitement des manifestations inflammatoires et/ou douloureuses

Info

Publication number
BE628497A
BE628497A BE628497A BE628497A BE628497A BE 628497 A BE628497 A BE 628497A BE 628497 A BE628497 A BE 628497A BE 628497 A BE628497 A BE 628497A BE 628497 A BE628497 A BE 628497A
Authority
BE
Belgium
Prior art keywords
inflammatory
treatment
new compound
painful manifestations
manifestations
Prior art date
Application number
BE628497A
Other languages
English (en)
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of BE628497A publication Critical patent/BE628497A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE628497A 1962-02-16 1963-02-15 Nouveau composé utilisable notamment pour le traitement des manifestations inflammatoires et/ou douloureuses BE628497A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR888318 1962-02-16

Publications (1)

Publication Number Publication Date
BE628497A true BE628497A (fr) 1963-08-16

Family

ID=8772897

Family Applications (1)

Application Number Title Priority Date Filing Date
BE628497A BE628497A (fr) 1962-02-16 1963-02-15 Nouveau composé utilisable notamment pour le traitement des manifestations inflammatoires et/ou douloureuses

Country Status (5)

Country Link
US (1) US3150047A (fr)
BE (1) BE628497A (fr)
CH (1) CH408915A (fr)
ES (1) ES284994A1 (fr)
GB (1) GB971243A (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232944A (en) * 1966-02-01 Monoglycerides 0f (carbgxy pl-ienyl amtno) chlgroqukngltnes
US3458519A (en) * 1966-05-02 1969-07-29 Parke Davis & Co Quinolylanthranilic acid compounds and methods for their production
FR2233059B1 (fr) * 1973-06-13 1976-09-03 Roussel Uclaf
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
SE448091B (sv) * 1977-12-15 1987-01-19 Roussel Uclaf Nya 2-/(4-kinolinyl)-amino/-5-fluorbensoesyraderivat, forfarande for framstellning derav samt farmaceutiska kompositioner innehallande dessa derivat
US20080139611A1 (en) * 2006-10-17 2008-06-12 Jan Wasley Methods of using 4-phenylaminoquinolines as topical non-steroidal antiinflammatory compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2138628A (en) * 1938-11-29 Hydroxy-ethoxy derivatives of
US1810267A (en) * 1927-12-07 1931-06-16 Winthrop Chem Co Inc Alkyl-quinolyl-amino-phenyl carboxylic acids
US2568778A (en) * 1948-05-28 1951-09-25 Sterling Drug Inc Tertiary-aminoalkyl-alpha-arylalpha-(4-quinolyl) acetates and amides and their preparation
US3024166A (en) * 1960-03-22 1962-03-06 Bristol Myers Co Analgesic dihydroxymethylbenzimidazol-2-ones
US3004889A (en) * 1960-05-16 1961-10-17 Bristol Myers Co Cyclobutane analgesics

Also Published As

Publication number Publication date
GB971243A (en) 1964-09-30
CH408915A (fr) 1966-03-15
ES284994A1 (es) 1963-04-01
US3150047A (en) 1964-09-22

Similar Documents

Publication Publication Date Title
NL268926A (nl) Oppervlaktebehandeling van metalen
BE613507A (fr) Procédé pour le traitement de surfaces métalliques
FR1444M (fr) Nouveau médicament notamment pour le traitement des irrégularités et des insuffisances ovariennes.
BE628497A (fr) Nouveau composé utilisable notamment pour le traitement des manifestations inflammatoires et/ou douloureuses
BE632037A (fr) Nouveau composé utilisable pour le traitement des manifestations inflammatoires ou douloureuses.
FR1396824A (fr) Traitement de surfaces en titane
FR1438M (fr) Nouveau médicament efficace dans le traitement de l'athérosclérose.
FR1242583A (fr) Solutions pour le traitement des pièces métalliques
FR2413M (fr) Nouveau médicament notamment pour le traitement des manifestations inflammatoires et douloureuses.
FR1729M (fr) Nouveau médicament notamment pour le traitement des manifestations inflammatoires et douloureuses.
FR1187M (fr) Nouveau médicament notamment pour le traitement des manifestations inflammatoires d'origine rhumatismale arthritique ou infectieuse.
FR1399M (fr) Nouveau médicament notamment pour le traitement de manifestations inflammatoires et douloureuses.
FR3187M (fr) Nouveau médicament notamment pour le traitement des irrégularites et des insuffisances ovariennes.
FR1385263A (fr) Perfectionnements au traitement des surfaces métalliques
FR2802M (fr) Nouveau médicament notamment pour le traitement des irrégularités et des insuffisances ovariennes.
FR2510M (fr) Nouveau médicament utilisable pour le traitement des infections staphylococciques et analogues.
BE630069A (fr) Composition thérapeutique pour le traitement du parkinsonisme.
FR1172M (fr) Nouveau médicament notamment pour le traitement des irrégularités et des insuffisances ovariennes.
FR1319135A (fr) Composition pour le traitement des métaux
FR1338926A (fr) Four pour le traitement de feuillards
FR1334211A (fr) Composition destinée au traitement des vins
FR1484M (fr) Nouveau médicament notamment pour le traitement des manifestations inflammatoires d'origine microbienne.
FR1535457A (fr) Bains ignés pour le traitement des surfaces métalliques
FR385M (fr) Nouveau médicament pour le traitement des infections staphylococciques et analogues.
FR2019M (fr) Nouveau thioéther utilisable en thérapeutique, notamment pour le traitement de diverses tumeurs solides.